Alembic’s affiliate Rhizen bags US FDA nod for oral lymphoma drug

Company says a critical cancer inhibiting component in the formulation is the first new chemical entity discovered by Indian scientists to secure US FDA nod

Topics


Rhizen pharma | Alembic Pharmaceuticals


Vinay Umarji  | 
Ahmedabad 


In what could further boost Alembic Pharmaceutical’s oncology business, its co-owned clinical-stage biopharmaceutical firm Rhizen Pharmaceuticals AG has bagged US Food and Drug Administration (USFDA) nod for an oral drug indicated in treating lymphoma.

Umbralisib is indicated for treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

According to Alembic Pharma managing director Pranav Amin, what sets the drug apart is that the novel next generation oral inhibitor of phosphoinositide 3 kinase (PI3K) delta is the first new chemical entity discovered by Indian scientists to secure a US FDA approval.

To be launched by early-next month in the US market, Umbralisib was discovered by Rhizen Pharma and subsequently licensed to Nasdaq-listed TG Therapeutics at an investigational new drug (IND) stage in 2012. Rhizen Pharmaceuticals is co-owned by Alembic Pharmaceuticals with 50 per cent stake while the rest is held by by Dr Swaroop Vakkalanka, the President & CEO of the company.

“Umralisib, which is a monotherapy treatment, offers the best choice for oncologists – particularly it can be a drug of choice for treatment of geriatric patients who need to be treated in the community cancer centers those who will be taking concomitant medications for other disorders such as blood-pressures, diabetes etc,” Vakkalanka explained.

In 2014, Rhizen Pharmaceuticals and TG Therapeutics entered into a licensing agreement as a part of which TG Therapeutics obtained worldwide rights while Rhizen retained commercialization rights for India. Also Rhizen remains the manufacturing and supply partner for Umbralisib.

Now, having then led the clinical development, TG Therapeutics has now bagged the regulator’s nod for the US market and will now market the novel drug under the brand name ‘Ukonig’. Rhizen would get high single digit royalty on net sales of the product globally, Amin stated.

Vakkalanka stated that the estimated market size for the drug is $7-8 billion per annum. “At peak sales, Ukoniq is expected to reach between $1-1.5 billion. That is the guidance given by our partner in the US. The launch is expected latest by early March,” Vakkalanka added.

On its part, Alembic Pharma expects another 9-12 months for data to be ready for working towards a launch in India. However, it needs to be mentioned here that the company is awaiting USFDA inspection for F2, F3 and F4 plants that will manufacture oncology injectables and oral solid dosage (OSD), general injectables as well as OSDs. Alembic Pharma currently runs three API plants, one formulations plant and one plant in Sikkim for the domestic market. Apart from this, the company runs three R&D centres with one each in Vadodara, Hyderabad and New Jersey.

The drug took around eight years since inception of phase one development in early 2013 to getting USFDA nod now. The trials were conducted globally with US being the major country, followed by countries in Europe, Australia and New Zealand and others.

Umbralisib was earlier granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read More

Spread the love
Nicholas ‘Nick’ Statman entered the property industry in 2001 and set up a property buying company that quickly established itself as one of the biggest in the sector. During this time the Company successfully transacted on thousands of residential properties across the UK. Nicholas Statman was an early pioneer of the ‘quick sale’ niche market which has since grown considerably with a multitude of companies now operating in the sector. Nicholas Statman has strategically built a sizeable residential and commercial property portfolio with a view to holding for optimum capital growth and a long term passive income. Nicholas Statman has been involved in almost every aspect of the property sector over a 20 year period – this includes buying and selling, development, letting and management and is now involved in the fast growing online/ hybrid Estate Agent industry.

Latest articles

A “Super League” is promising to make African soccer...

African soccer is getting a new annual club competition that may generate money for participants at a scale never seen before in the continent.At least that’s the hope for the Africa Super League.The tournament will boost the “quality and competitiveness of football in Africa,” in part with the $100 million prize money attached, according to…

India has a term for Europe’s planned power outages...

Europe’s plan to overcome its weighing power cuts, Germany is proposing France and increasingly warms its summers and based on cost considerations, regulatory mechanisms, and utilisation levels of coal plants.“India’s grid is under increasing pressure from the rapid growth in load from commercial and residential air conditioners, refrigeration and other loads, boosting electricity consumption at…

The number of foreign companies active in India is...

Foreign companies may be losing interest in India.While more of them have registered in the country—up 11.4% since 2017—fewer are active compared to then, 2,783 foreign companies left India, commerce and industry minister Piyush Goyal told parliament late last year. These include Metro AG, Holcim, Ford, Royal Bank of Scotland, ease of doing business in…

No, Elden Ring And GTA V Are Not On...

Earlier this week, some folks checking Microsoft’s Cloud Gaming beta website noticed something weird: listings for games like Elden Ring and Grand Theft Auto V not only said they were part of the company’s Game Pass offering, but would also be playable on the cloud.Read more...

Similar articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Subscribe to our newsletter

Spread the love